Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Fase 3 utvidelsesstudie for å evaluere langsiktig sikkerhet for Ianalumab hos deltakere med systemisk lupus erythematosus (SIRIUS-SLE forlengelse). (SIRIUS-SLE LTE)

6. november 2026 oppdatert av: Novartis Pharmaceuticals

A Randomized, Double-blind, Placebo-controlled Extension Study, Followed by a Study Treatment Withdrawal or Open-label Period, to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)

The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

The purpose of this extension study is to evaluate long-term safety and tolerability of ianalumab administered s.c. monthly or quarterly, compared to monthly placebo, in adolescent and adult participants with anti-nuclear antibody (ANA)-positive systemic lupus erythematosus of moderate-to-severe disease activity, who have completed either CVAY736F12301 (SIRIUS-SLE 1) or CVAY736F12302 (SIRIUS-SLE 2) core studies.

This extension study will last up to 7 years and includes the following three treatment periods:

  • a 3-year double-blind, randomized, placebo-controlled treatment period, evaluating the safety and efficacy of ianalumab or placebo (Period 1);
  • followed by a 2-year treatment period evaluating safety and efficacy of treatment withdrawal and open-label ianalumab administered s.c. monthly.
  • and an up to 2-year open-label, safety monitoring period (Period 3).

Studietype

Intervensjonell

Registrering (Antatt)

550

Fase

  • Fase 3

Utvidet tilgang

Tilgjengelig utenfor den kliniske utprøvingen. Se utvidet tilgangspost.

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Caba, Argentina, C1015ABO
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Caba, Argentina, C1427CCL
        • Rekruttering
        • Novartis Investigative Site
      • San Miguel de Tucumán, Argentina, T4000AXL
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Buenos Aires
      • La Plata, Buenos Aires, Argentina, B1900AWT
        • Rekruttering
        • Novartis Investigative Site
      • Quilmes, Buenos Aires, Argentina, 1878
        • Rekruttering
        • Novartis Investigative Site
      • San Miguel, Buenos Aires, Argentina, B1663GKT
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Tucumán Province
      • San Miguel, Tucumán Province, Argentina, T4000CBC
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Queensland
      • Maroochydore, Queensland, Australia, 4558
        • Rekruttering
        • Novartis Investigative Site
      • Salvador, Brasil, 40323-010
        • Rekruttering
        • Novartis Investigative Site
    • Espírito Santo
      • Vitória, Espírito Santo, Brasil, 29055-450
        • Rekruttering
        • Novartis Investigative Site
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasil, 40150-150
        • Rekruttering
        • Novartis Investigative Site
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brasil, 30150-221
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Paraná
      • Curitiba, Paraná, Brasil, 80030-110
        • Rekruttering
        • Novartis Investigative Site
    • Rio de Janeiro
      • Niterói, Rio de Janeiro, Brasil, 24020-096
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Rio de Janeiro, Rio de Janeiro, Brasil, 22211-230
        • Rekruttering
        • Novartis Investigative Site
    • São Paulo
      • Barretos, São Paulo, Brasil, 14784-400
        • Rekruttering
        • Novartis Investigative Site
      • São Paulo, São Paulo, Brasil, 04038-002
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • São Paulo, São Paulo, Brasil, 01244-030
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Sofia, Bulgaria, 1431
        • Rekruttering
        • Novartis Investigative Site
    • Bulgaria
      • Plovdiv, Bulgaria, Bulgaria, 4002
        • Rekruttering
        • Novartis Investigative Site
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 1L7
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Ontario
      • Toronto, Ontario, Canada, M5T 2S8
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Quebec
      • Rimouski, Quebec, Canada, G5L 5T1
        • Rekruttering
        • Novartis Investigative Site
    • Los Ríos Region
      • Valdivia, Los Ríos Region, Chile, 5110683
        • Rekruttering
        • Novartis Investigative Site
    • RM
      • Santiago, RM, Chile, 7500588
        • Rekruttering
        • Novartis Investigative Site
    • Santiago Metropolitan
      • Santiago, Santiago Metropolitan, Chile, 7500710
        • Rekruttering
        • Novartis Investigative Site
      • Bogotá, Colombia, 111211
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Antioquia
      • Medellín, Antioquia, Colombia, 050001
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Atlántico
      • Barranquilla, Atlántico, Colombia, 080020
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Cundinamarca
      • Chía, Cundinamarca, Colombia, 250001
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Santander Department
      • Bucaramanga, Santander Department, Colombia, 680003
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Valle del Cauca Department
      • Cali, Valle del Cauca Department, Colombia, 760046
        • Rekruttering
        • Novartis Investigative Site
    • Alabama
      • Anniston, Alabama, Forente stater, 36207
        • Rekruttering
        • Pinnacle Research Group Llc
        • Hovedetterforsker:
          • Vishala L Chindalore
        • Ta kontakt med:
    • California
      • Burbank, California, Forente stater, 91505
        • Rekruttering
        • Providence Medical Center
        • Hovedetterforsker:
          • Sue Chung
        • Ta kontakt med:
      • La Palma, California, Forente stater, 90623
        • Rekruttering
        • Advanced Medical Research
        • Hovedetterforsker:
          • Gerald Ho
        • Ta kontakt med:
      • Westlake Village, California, Forente stater, 91361
        • Aktiv, ikke rekrutterende
        • Millennium Clinical Trials
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • Rekruttering
        • University of Colorado Denver
        • Hovedetterforsker:
          • Christopher Striebich
        • Ta kontakt med:
    • Florida
      • Clearwater, Florida, Forente stater, 33765
        • Rekruttering
        • Clinical Res Of W Florida
        • Hovedetterforsker:
          • Robert Levin
        • Ta kontakt med:
      • Cooper City, Florida, Forente stater, 33024
        • Rekruttering
        • GNP Research
        • Hovedetterforsker:
          • Mark Jaffe
        • Ta kontakt med:
      • Homestead, Florida, Forente stater, 33033
        • Rekruttering
        • Homestead Assoc In Research Inc
        • Hovedetterforsker:
          • Gilberto Seco
        • Ta kontakt med:
      • Plantation, Florida, Forente stater, 33324
        • Rekruttering
        • IRIS Research and Development
        • Hovedetterforsker:
          • Guillermo Valenzuela
        • Ta kontakt med:
      • Tampa, Florida, Forente stater, 33603
        • Rekruttering
        • Clinical Research of West Florida Inc
        • Hovedetterforsker:
          • John Carter
        • Ta kontakt med:
    • Georgia
      • Lawrenceville, Georgia, Forente stater, 30044
        • Rekruttering
        • Parris and Associates Rheumatology
        • Hovedetterforsker:
          • Glenn Parris
        • Ta kontakt med:
    • Illinois
      • Skokie, Illinois, Forente stater, 60076
        • Fullført
        • Robert A Hozman MD SC
      • Willowbrook, Illinois, Forente stater, 60527
        • Rekruttering
        • Willow Rheumatology Wellness
        • Hovedetterforsker:
          • Angela R Crowley
        • Ta kontakt med:
    • Louisiana
      • Lake Charles, Louisiana, Forente stater, 70601
      • New Orleans, Louisiana, Forente stater, 70112
        • Aktiv, ikke rekrutterende
        • UMC New Orleans
    • Maryland
      • Baltimore, Maryland, Forente stater, 21201
        • Aktiv, ikke rekrutterende
        • University Of Maryland
    • Michigan
      • Detroit, Michigan, Forente stater, 48202
        • Rekruttering
        • Henry Ford Health
        • Hovedetterforsker:
          • Alireza Meysami
        • Ta kontakt med:
      • Grand Blanc, Michigan, Forente stater, 48439
        • Rekruttering
        • Ahmed Arif Medical Research Center
        • Hovedetterforsker:
          • Ali Karrar
        • Ta kontakt med:
          • Iman Abdelrahman
          • Telefonnummer: +1 810 953 8700
          • E-post: iman@aamrc.net
    • Ohio
      • Middleburg Heights, Ohio, Forente stater, 44130
        • Rekruttering
        • Paramount Med Rsrch and Consult LLC
        • Hovedetterforsker:
          • Isam Diab
        • Ta kontakt med:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15213
        • Rekruttering
        • University Of Pittsburgh
        • Hovedetterforsker:
          • Andreea Coca
        • Ta kontakt med:
    • Tennessee
      • Jackson, Tennessee, Forente stater, 38305
        • Rekruttering
        • West Tennessee Research Institute
        • Hovedetterforsker:
          • Jacob A Aelion
        • Ta kontakt med:
      • Memphis, Tennessee, Forente stater, 38119
        • Rekruttering
        • Shelby Research LLC
        • Hovedetterforsker:
          • Ramesh C Gupta
        • Ta kontakt med:
    • Texas
      • Bellaire, Texas, Forente stater, 77401
        • Rekruttering
        • Novel Research LLC
        • Hovedetterforsker:
          • Wajeeha Yousaf
        • Ta kontakt med:
      • League City, Texas, Forente stater, 77573
      • Red Oak, Texas, Forente stater, 75154
        • Rekruttering
        • Epic Medical Research
        • Hovedetterforsker:
          • Sunny Patel
        • Ta kontakt med:
      • Montpellier, Frankrike, 34295
        • Rekruttering
        • Novartis Investigative Site
      • Paris, Frankrike, 75014
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Paris, Frankrike, 75013
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Toulouse, Frankrike, 31059
        • Rekruttering
        • Novartis Investigative Site
      • Toulouse, Frankrike, 31054
        • Rekruttering
        • Novartis Investigative Site
      • Guatemala City, Guatemala, 01010
        • Rekruttering
        • Novartis Investigative Site
    • Departamento de Guatemala
      • Guatemala City, Departamento de Guatemala, Guatemala, 01010
        • Rekruttering
        • Novartis Investigative Site
      • New Delhi, India, 110075
        • Rekruttering
        • Novartis Investigative Site
    • Gujarat
      • Ahmedabad, Gujarat, India, 380015
        • Rekruttering
        • Novartis Investigative Site
      • Ahmedabad, Gujarat, India, 380006
        • Rekruttering
        • Novartis Investigative Site
    • Kerala
      • Kozhikode, Kerala, India, 673008
        • Rekruttering
        • Novartis Investigative Site
    • Maharashtra
      • Kolhāpur, Maharashtra, India, 416001
        • Rekruttering
        • Novartis Investigative Site
      • Nagpur, Maharashtra, India, 441108
        • Rekruttering
        • Novartis Investigative Site
      • Nashik, Maharashtra, India, 422101
        • Rekruttering
        • Novartis Investigative Site
      • Pune, Maharashtra, India, 411001
        • Rekruttering
        • Novartis Investigative Site
      • Pune, Maharashtra, India, 411007
        • Rekruttering
        • Novartis Investigative Site
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, India, 110060
        • Rekruttering
        • Novartis Investigative Site
    • New Delhi
      • New Delhi, New Delhi, India, 110029
        • Rekruttering
        • Novartis Investigative Site
    • Uttarakhand
      • Dehradun, Uttarakhand, India, 248001
        • Rekruttering
        • Novartis Investigative Site
      • Haifa, Israel, 3109601
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Ramat Gan, Israel, 5265601
        • Rekruttering
        • Novartis Investigative Site
    • FE
      • Cona, FE, Italia, 44124
        • Rekruttering
        • Novartis Investigative Site
    • PD
      • Padova, PD, Italia, 35128
        • Rekruttering
        • Novartis Investigative Site
    • PI
      • Pisa, PI, Italia, 56126
        • Rekruttering
        • Novartis Investigative Site
    • RM
      • Roma, RM, Italia, 00152
        • Rekruttering
        • Novartis Investigative Site
    • TO
      • Torino, TO, Italia, 10128
        • Rekruttering
        • Novartis Investigative Site
      • Miyazaki, Japan, 8891692
        • Rekruttering
        • Novartis Investigative Site
      • Osaka, Japan, 5458586
        • Rekruttering
        • Novartis Investigative Site
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 4578510
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Nagoya, Aichi-ken, Japan, 4578511
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Hokkaido
      • Sapporo, Hokkaido, Japan, 0608648
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Kanagawa
      • Yokohama, Kanagawa, Japan, 2360004
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Miyagi
      • Sendai, Miyagi, Japan, 9838512
        • Rekruttering
        • Novartis Investigative Site
    • Tokyo
      • Bunkyo-ku, Tokyo, Japan, 1138519
        • Rekruttering
        • Novartis Investigative Site
      • Chuo Ku, Tokyo, Japan, 1048560
        • Rekruttering
        • Novartis Investigative Site
      • Fuchū, Tokyo, Japan, 1838524
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Shinjuku-ku, Tokyo, Japan, 1608582
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • tabashi City, Tokyo, Japan, 1738610
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Beijing, Kina, 100730
        • Rekruttering
        • Novartis Investigative Site
      • Beijing, Kina, 100069
        • Rekruttering
        • Novartis Investigative Site
      • Shanghai, Kina, 200001
        • Rekruttering
        • Novartis Investigative Site
      • Xinxiang, Kina, 453099
        • Rekruttering
        • Novartis Investigative Site
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510080
        • Rekruttering
        • Novartis Investigative Site
      • Guangzhou, Guangdong, Kina, 510000
        • Rekruttering
        • Novartis Investigative Site
      • Shantou, Guangdong, Kina, 515000
        • Rekruttering
        • Novartis Investigative Site
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210008
        • Rekruttering
        • Novartis Investigative Site
      • Suzhou, Jiangsu, Kina, 215004
        • Rekruttering
        • Novartis Investigative Site
    • Jiangxi
      • Nanchang, Jiangxi, Kina, 330006
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Pingxiang, Jiangxi, Kina, 337000
        • Rekruttering
        • Novartis Investigative Site
    • Jilin
      • Changchun, Jilin, Kina, 130021
        • Rekruttering
        • Novartis Investigative Site
    • Shandong
      • Linyi, Shandong, Kina, 276100
        • Rekruttering
        • Novartis Investigative Site
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
        • Rekruttering
        • Novartis Investigative Site
    • Xinjiang
      • Ürümqi, Xinjiang, Kina, 830001
        • Rekruttering
        • Novartis Investigative Site
    • Zhejiang
      • Ningbo, Zhejiang, Kina, 315016
        • Rekruttering
        • Novartis Investigative Site
      • Wenzhou, Zhejiang, Kina, 325000
        • Rekruttering
        • Novartis Investigative Site
    • Perak
      • Ipoh, Perak, Malaysia, 30450
        • Rekruttering
        • Novartis Investigative Site
      • México, Mexico, 07760
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Guanajuato
      • León, Guanajuato, Mexico, 37160
        • Rekruttering
        • Novartis Investigative Site
    • Jalisco
      • Guadalajara, Jalisco, Mexico, 44160
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Mexico City
      • Mexico City, Mexico City, Mexico, 06700
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Michoacán
      • Morelia, Michoacán, Mexico, 58000
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Yucatán
      • Mérida, Yucatán, Mexico, 97070
        • Rekruttering
        • Novartis Investigative Site
      • Bydgoszcz, Polen, 85-065
        • Rekruttering
        • Novartis Investigative Site
      • Bydgoszcz, Polen, 85-168
        • Rekruttering
        • Novartis Investigative Site
      • Bytom, Polen, 41 902
        • Rekruttering
        • Novartis Investigative Site
      • Warsaw, Polen, 00-874
        • Rekruttering
        • Novartis Investigative Site
      • Warsaw, Polen, 04-141
        • Rekruttering
        • Novartis Investigative Site
    • Lower Silesian Voivodeship
      • Wroclaw, Lower Silesian Voivodeship, Polen, 52-210
        • Rekruttering
        • Novartis Investigative Site
      • Braga, Portugal, 4710-243
        • Rekruttering
        • Novartis Investigative Site
      • Lisbon, Portugal, 1050-034
        • Rekruttering
        • Novartis Investigative Site
      • Brasov, Romania, 500283
        • Rekruttering
        • Novartis Investigative Site
      • Bucharest, Romania, 011172
        • Rekruttering
        • Novartis Investigative Site
    • Cluj
      • Cluj-Napoca, Cluj, Romania, 400006
        • Rekruttering
        • Novartis Investigative Site
      • Bratislava, Slovakia, 811 08
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Košice, Slovakia, 040 01
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Barcelona, Spania, 08035
        • Rekruttering
        • Novartis Investigative Site
      • Madrid, Spania, 28034
        • Rekruttering
        • Novartis Investigative Site
      • Valencia, Spania, 46014
        • Rekruttering
        • Novartis Investigative Site
    • A Coruna
      • Santiago Compostela, A Coruna, Spania, 15706
        • Rekruttering
        • Novartis Investigative Site
    • Barcelona
      • Badalona, Barcelona, Spania, 08916
        • Rekruttering
        • Novartis Investigative Site
    • Cantabria
      • Santander, Cantabria, Spania, 39008
        • Rekruttering
        • Novartis Investigative Site
    • Catalonia
      • Barcelona, Catalonia, Spania, 08003
        • Rekruttering
        • Novartis Investigative Site
    • Madrid
      • San Sebastian Reyes, Madrid, Spania, 28702
        • Rekruttering
        • Novartis Investigative Site
      • Gwangju, Sør -Korea, 61469
        • Fullført
        • Novartis Investigative Site
      • Seoul, Sør -Korea, 06591
        • Rekruttering
        • Novartis Investigative Site
      • Seoul, Sør -Korea, 04763
        • Rekruttering
        • Novartis Investigative Site
      • Umhlanga, Sør-Afrika, 4320
        • Rekruttering
        • Novartis Investigative Site
    • Gauteng
      • Pretoria, Gauteng, Sør-Afrika, 0002
        • Rekruttering
        • Novartis Investigative Site
    • Western Cape
      • Cape Town, Western Cape, Sør-Afrika, 7500
        • Rekruttering
        • Novartis Investigative Site
      • Cape Town, Western Cape, Sør-Afrika, 7405
        • Rekruttering
        • Novartis Investigative Site
      • Somerset West, Western Cape, Sør-Afrika, 7130
        • Rekruttering
        • Novartis Investigative Site
      • Kaohsiung City, Taiwan, 833
        • Rekruttering
        • Novartis Investigative Site
      • Taichung, Taiwan, 40447
        • Rekruttering
        • Novartis Investigative Site
      • Taichung, Taiwan, 407219
        • Rekruttering
        • Novartis Investigative Site
      • Taipei, Taiwan, 10002
        • Rekruttering
        • Novartis Investigative Site
      • Taipei, Taiwan, 11217
        • Rekruttering
        • Novartis Investigative Site
      • Taoyuan, Taiwan, 33305
        • Rekruttering
        • Novartis Investigative Site
      • Bangkok, Thailand, 10400
        • Rekruttering
        • Novartis Investigative Site
      • Bangkok, Thailand, 10700
        • Rekruttering
        • Novartis Investigative Site
    • Hat Yai
      • Songkhla, Hat Yai, Thailand, 90110
        • Rekruttering
        • Novartis Investigative Site
    • Thailand
      • Muang, Thailand, Thailand, 12120
        • Rekruttering
        • Novartis Investigative Site
      • Brno, Tsjekkia, 638 00
        • Rekruttering
        • Novartis Investigative Site
      • Prague, Tsjekkia, 128 00
        • Rekruttering
        • Novartis Investigative Site
      • Uherské Hradiště, Tsjekkia, 686 01
        • Rekruttering
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Tyskland, 50937
        • Tilbaketrukket
        • Novartis Investigative Site
    • Saxony
      • Leipzig, Saxony, Tyskland, 04103
        • Rekruttering
        • Novartis Investigative Site
      • Budapest, Ungarn, 1134
        • Rekruttering
        • Novartis Investigative Site
      • Gyula, Ungarn, 5700
        • Rekruttering
        • Novartis Investigative Site
      • Zalaegerszeg, Ungarn, 8900
        • Rekruttering
        • Novartis Investigative Site
    • Fejér
      • Székesfehérvár, Fejér, Ungarn, 8000
        • Rekruttering
        • Novartis Investigative Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

12 år til 100 år (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

  • Signed informed consent prior to participation in the extension study. Parent or legal guardian's signed informed consent and child's assent, if appropriate, are required before any assessment is performed for participants <18 years of age. Of note, if the participant reaches age of consent (age as per local law) during the study, they will also need to sign the corresponding study Informed Consent Form (ICF) at the next study visit.
  • Participants must have participated in either one of the two SIRIUS-SLE core studies, CVAY736F12301 or CVAY736F12302, and have completed the treatment period through Week 60 without treatment discontinuation.
  • In the judgement of the investigator, participants must be expected to clinically benefit from continued study treatment.

Key Exclusion Criteria:

  • Use of prohibited therapies.
  • Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for clinically significant infection which in the opinion of the investigator will place the participant at risk for participation.
  • Plans for administration of live vaccines during the study period.
  • Pregnant or nursing (lactating) women.

Other protocol-defined inclusion/exclusion criteria may apply.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Ianalumab monthly

Ianalumab s.c. monthly

Ianalumab s.c. monthly Ianalumab s.c. quarterly

Andre navn:
  • VAY736
Eksperimentell: Ianalumab quarterly

Ianalumab s.c. quarterly

Ianalumab s.c. monthly Ianalumab s.c. quarterly

Andre navn:
  • VAY736
Placebo komparator: Placebo monthly

Placebo s.c. monthly

Placebo s.c. monthly

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of treatment-emergent Adverse events/Serious Adverse events
Tidsramme: through study completion, up to approximately 324 weeks

Assessment of long-term safety and tolerability of ianalumab

through study completion, up to approximately 324 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of participants who achieved Systemic Lupus Erythematosus Responder Index -4 (SRI-4) response
Tidsramme: up to Week 324

SRI-4 response is defined as:

  • Systemic Lupus Erythematosus Disease Activity Index - 2000 (SLEDAI-2K) reduction from baseline of ≥ 4 points
  • No British Isles Lupus Assessment Group-2004 (BILAG-2004) worsening, defined as ≥ 1 new A or ≥ 2 new B items compared to baseline
  • No worsening in Physician Global Assessment of Disease Activity (PhGA), defined as an increase of ≥ 0.3 from baseline on a 0 to 3 visual analog scale
up to Week 324
Proportion of participants who achieved Definition of Remission in SLE (DORIS) response
Tidsramme: up to Week 324

DORIS is defined as:

  • Clinical SLEDAI (cSLEDAI) = 0 (excluding serological items, anti-dsDNA and complement)
  • Physician global assessment (PhGA, scale 0-3) < 0.5
  • Current CS (predniso(lo)ne or equivalent) dose ≤ 5 mg/day
  • Patient may be on antimalarials, low dose glucocorticoids and/or stable immune-suppressive treatment including biologics.
up to Week 324
Change in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index
Tidsramme: up to Week 324

SLICC/ACR Damage Index is a measure of cumulative damage due to SLE

up to Week 324
Average daily dose of corticosteroids administered
Tidsramme: up to Week 324

Evaluating the effect of ianalumab on corticosteroids intake

up to Week 324
Annualized BILAG moderate or severe flare rate
Tidsramme: up to Week 324

Annualized BILAG moderate or severe flare rate where moderate BILAG flare is defined as 2 or more new BILAG-2004 B items, and severe BILAG flare is defined as 1 or more new BILAG-2004 A items, compared to the previous visit

up to Week 324
Ianalumab serum concentrations during treatment and follow-up after last dose
Tidsramme: up to Week 324

To characterize the Pharmacokinetics (PK) of ianalumab

up to Week 324
Incidence and titer of anti-ianalumab antibodies in serum (ADA assay) over time.
Tidsramme: up to Week 324

To characterize the immunogenicity of ianalumab

up to Week 324

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

21. mai 2024

Primær fullføring (Antatt)

3. april 2034

Studiet fullført (Antatt)

2. oktober 2034

Datoer for studieregistrering

Først innsendt

2. oktober 2023

Først innsendt som oppfylte QC-kriteriene

15. november 2023

Først lagt ut (Faktiske)

18. november 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • CVAY736F12301E1
  • 2023-505929-14-00 (Registeridentifikator: EU CT NUMBER)
  • 2023 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere